Pembroke Management LTD Has $35.36 Million Stock Position in Cellebrite DI Ltd. $CLBT

Key Points

• Pembroke Management LTD has reduced its holdings in Cellebrite DI Ltd. by 8.7%, now owning approximately 1,819,628 shares, which represents 5.2% of its total portfolio.
• Recent analyst ratings have been mixed, with price targets reduced by several firms, including JPMorgan Chase lowering theirs from $29.00 to $25.00, while Wall Street Zen upgraded it from "hold" to "buy."
• Cellebrite DI reported a revenue increase to $113.28 million for the most recent quarter, beating analysts' expectations and reflecting an 18.4% year-over-year growth.

Pembroke Management LTD reduced its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 8.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,819,628 shares of the company's stock after selling 172,804 shares during the quarter. Cellebrite DI comprises approximately 5.2% of Pembroke Management LTD's investment portfolio, making the stock its 2nd largest position. Pembroke Management LTD owned about 0.76% of Cellebrite DI worth $35,355,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. NewEdge Advisors LLC lifted its stake in shares of Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after acquiring an additional 3,352 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of Cellebrite DI in the fourth quarter valued at approximately $1,015,000. Public Employees Retirement Association of Colorado bought a new stake in Cellebrite DI during the fourth quarter valued at $465,000. Northern Trust Corp grew its stake in Cellebrite DI by 113.6% in the 4th quarter. Northern Trust Corp now owns 211,994 shares of the company's stock valued at $4,670,000 after buying an additional 112,731 shares in the last quarter. Finally, AQR Capital Management LLC bought a new position in shares of Cellebrite DI during the fourth quarter valued at about $16,205,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Trading Down 0.2%

CLBT traded down $0.04 on Tuesday, reaching $16.36. The stock had a trading volume of 1,600,415 shares, compared to its average volume of 1,676,761. The company has a market cap of $3.92 billion, a P/E ratio of -21.53, a price-to-earnings-growth ratio of 2.98 and a beta of 1.28. The business's 50-day moving average price is $15.00 and its two-hundred day moving average price is $17.10. Cellebrite DI Ltd. has a 12-month low of $13.10 and a 12-month high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.11 by $0.01. The firm had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business's revenue for the quarter was up 18.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Lake Street Capital reduced their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a report on Friday, August 15th. JPMorgan Chase & Co. cut their target price on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Needham & Company LLC cut their price target on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Finally, Wall Street Zen raised Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $22.40.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.